Thomas Dubensky

Thomas Dubensky

Chief Executive Officer at
ImmuneSensor Therapeutics, Inc.
68 year
Health Technology
Commercial Services
Consumer Services

Profile

Thomas W.
Dubensky
was the founder of Anza Therapeutics, Inc. (2007), holding the title of Chief Scientific Officer in 2010.
Dr. Dubensky is the founder of ImmuneSensor Therapeutics, Inc., serving as President, Chief Executive Officer & Director since 2024.
Former positions include Chief Executive Officer & Director at TempestTx, Inc., Scientific Director at Chiron Corp., Director at HTG Molecular Diagnostics, Inc. (2022-2023), President & Director at Tempest Therapeutics, Inc. (2017-2023), Vice President at Onyx Pharmaceuticals, Inc., Vice President-Research at Cerus Corp.
(2002-2007), Chief Scientific Officer at Aduro BioTech, Inc. (2011-2017), Principal at Chiron Viagene, Inc., and Chief Scientific Officer at Immune Design Corp.
Education includes an undergraduate degree from the University of California, Berkeley and a doctorate from the University of Colorado Health Sciences Center.

Thomas Dubensky active positions

CompaniesPositionStart
Chief Executive Officer 01/05/2024

Former positions of Thomas Dubensky

CompaniesPositionEnd
TEMPEST THERAPEUTICS, INC. President 15/09/2023
HTG MOLECULAR DIAGNOSTICS, INC. Director/Board Member 01/08/2023
CHINOOK THERAPEUTICS, INC. Chief Tech/Sci/R&D Officer 31/08/2017
CERUS CORPORATION Chief Tech/Sci/R&D Officer 16/11/2007
Chief Executive Officer -
See the detail of Thomas Dubensky's experience

Training of Thomas Dubensky

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

49

1st degree connections

13

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies13

Health Technology

Health Technology

Health Technology

Commercial Services

Health Technology

Health Technology

Commercial Services

Consumer Services

Consumer Services

Health Technology

Health Technology

Commercial Services

Health Technology

  1. Stock Market
  2. Insiders
  3. Thomas Dubensky